Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Regeneron expects continuing demand for its COVID-19 therapy

05/06/2021 | 11:16am EDT
FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown

(Reuters) -Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday and said it expects demand for its COVID-19 antibody therapy to hold up even as vaccination efforts across the United States intensify.

The comments were in contrast to those by rival Eli Lilly and Co, which last month trimmed its 2021 profit target as demand for Lilly's COVID-19 antibody therapies took a hit due to vaccinations.

Lilly's antibody therapies and Regeneron's REGEN-COV have been authorized in the U.S. for treating non-hospitalized COVID-19 patients, and the companies have signed supply agreements with the U.S. government worth millions.

Demand for these therapies, however, has been lackluster due to the complexities involved in their administration.

Still, Regeneron said its therapy brought in U.S. sales of $262 million in the first quarter, ahead of estimates of $255 million, according to brokerage Piper Sandler.

"Despite high rates of vaccination, it's estimated that tens of millions will remain unvaccinated in the U.S. alone," Regeneron Chief Executive Officer Leonard Schleifer said.

Regeneron is also pursuing U.S. authorization of a lower dose of its antibody cocktail and for its use as a preventive medicine. It has reported positive data for both from clinical studies.

The drugmaker said it expects a decision from the U.S. health regulator on the authorization of the lower 1.2 g dose over the next several weeks.

Given the success of the lower dose based on trial data, REGEN-COV's sales will remain strong even during the second half of 2021, after Regeneron's supply contract with the United States is filled in the second quarter, Cowen analyst Yaron Werber said.

Regeneron's shares rose 2% to $490.90 after it beat estimates for first-quarter profit, helped in part by a recovery in demand for its physician-administered eye drug Eylea.

(Reporting by Mrinalika Roy and Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)

By Mrinalika Roy and Manojna Maddipatla

ę Reuters 2021
Latest news "Economy & Forex"
05:51pNEW ZEALAND GOVERNMENTá : Feedback sought on future of housing and urban development
05:11pJudge tosses Houston hospital workers' lawsuit over vaccine requirement
04:23pNPS NATIONAL PARK SERVICEá : Opportunity to cut and remove hay
04:11pU.S. CDC Reports Total Deaths Of 597,195 Due To Coronavirus As Of Yesterday Versus 596,971 In Previous Report On June 12
04:11pU.s. cdc reports total novel coronavirus cases of 33,283,781 as of yesterday vs 33,272,062 in previous report on june 12
04:11pNew israeli pm bennett spoke to biden, described him as a 'great friend of israel' - bennett's office
04:09pU.s. cdc reports total deaths of 597,195 due to coronavirus as of yesterday vs 596,971 in previous report on june 12
04:05pU.s. cdc says 143,921,222 individuals have been fully vaccinated against covid-19 as of june 13 vs 143,119,077 individuals as of june 12
04:03pU.s. cdc says 173,840,483 individuals have received at least one dose of covid-19 vaccine as of june 13 vs 173,391,711 individuals as of june 12
04:02pU.s. cdc says administered 309,322,545 doses of covid-19 vaccine as of june 13 vs 308,112,728 doses administered as of june 12
Latest news "Economy & Forex"